Last reviewed · How we verify
Recombinant zoster vaccination
At a glance
| Generic name | Recombinant zoster vaccination |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Recombinant Herpes Zoster Vaccine for Prevention of Cardiovascular Events and Dementia (PHASE4)
- Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases Under Immunomodulators (PHASE4)
- Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population (PHASE1, PHASE2)
- Immunogenicity, Efficacy and Safety of Recombinant Herpes Zoster Vaccine in Frail Patients
- Shingrix In Recipients of Allogeneic Transplants (PHASE2)
- Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above (PHASE2)
- Vaccine Responses in Cancer
- Immunogenicity and Safety of Recombinant Zoster Vaccine in People Living With HIV (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Recombinant zoster vaccination CI brief — competitive landscape report
- Recombinant zoster vaccination updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI